

Overview of key presentations featuring Genentech medicines at ASH 2025

Medicine	Abstract Title / Study Focus	Abstract Number / Presentation Details	Session / Study Phase	Date & Time
Cevostamab	Tumor clearance, T-cell fitness and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 arm B	#252 Oral Presentation	Session 654 — Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma	Saturday, December 6, 2025 – 3:15 PM EST
Cevostamab (subcutaneous)	First data from Phase Ib CAMMA-3 study: Subcutaneous cevostamab monotherapy delivers deep and durable responses in people with late-line R/R multiple myeloma	Poster Presentation (Phase Ib)	Multiple Myeloma – New Therapies and Biomarker Analyses	December 6–9, 2025
Hemlibra® (emicizumab-kxwh)	Post-marketing data from the Beyond ABR study: Low bleeding rates and improved joint health after switching to Hemlibra prophylaxis from factor VIII	Poster Presentation	Hemophilia A – Real-World Outcomes	December 6–9, 2025
NXT007	Positive Phase I/II results: New global study data in people with hemophilia A with and without factor VIII inhibitors, supporting normalization of hemostasis	Oral / Poster (Phase I/II)	Hemophilia A – Emerging Therapies	December 6–9, 2025
SPK-8011QQ	Pre-clinical data showing enhanced hemostatic potency versus SPK-8011 in ex vivo and in vivo models; supports ongoing evaluation of next-generation AAV gene therapy	Poster Presentation (Pre-clinical)	Gene Therapy – Novel Vectors	December 6–9, 2025
Lunsumio® (mosune tuzumab-axgb)	Preliminary data from U.S. extension arm of Phase III CELESTIMO study: Lunsumio + lenalidomide as effective, well-tolerated outpatient therapy in 2L+ R/R follicular lymphoma	Oral / Poster (Phase III)	Lymphoma – Relapsed/Refractory Follicular	December 6–9, 2025
Lunsumio + Polivy® (polatuzumab vedotin-piiq)	Long-term follow-up from GO40516: Sustained improvements in ORR and PFS; patient-reported outcomes from SUNMO show delayed deterioration and improved QoL in transplant-ineligible R/R LBCL	Poster Presentation (Phase Ib/II & Phase III)	Lymphoma – Large B-Cell: Combination Therapies	December 6–9, 2025
Columvi® (glofitamab-gxmb)	Three-year follow-up and subgroup analyses from Phase III STARGLO: Continued superior survival outcomes with Columvi + GemOx vs Rituxan + GemOx in R/R DLBCL	Oral / Poster (Phase III)	Diffuse Large B-Cell Lymphoma – Survival Outcomes	December 6–9, 2025